{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:10:04Z","timestamp":1789229404941,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Zuojin formula, a traditional Chinese medicine, comprises <jats:italic>Coptis chinensis<\/jats:italic> and <jats:italic>Evodia rutaecarpa<\/jats:italic>. In our previous study, the total alkaloid extract from Zuojin formula (TAZF) showed potent and improved efficacy. However, its safety and toxicokinetics remain unknown. The objective of this study was to evaluate the safety of repeated administrations of TAZF and investigate the internal exposure of the main components and its relationship with toxic symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sprague\u2013Dawley rats were orally administered TAZF at 0.4, 1.2 and 3.7\u2009g\/kg for 28\u2009days, which was followed by a 14-day recovery period. The toxic effects were evaluated weekly by assessing body weight changes, food intake, blood biochemistry and haematological indices, organ weights and histological changes. A total of eight components were detected, including berberine, coptisine, epiberberine, palmatine, jatrorrhizine, columbamine, evodiamine, and rutaecarpine. The toxicokinetic profiles of the eight components were investigated after single and repeated administrations. Linear mixed effect models were applied to analyse the associations between internal exposure and toxic symptoms. Network pharmacology analysis was applied to explore the potential toxic mechanisms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the vehicle group, the rats in the low- and medium-dose groups did not show noticeable abnormal changes, while rats in the high-dose group exhibited inhibition of weight gain, a slight reduction in food consumption, abdominal bloating and atrophy of the splenic white pulp during drug administration. The concentration of berberine in plasma was the highest among all compounds. Epiberberine was found to be associated with the inhibition of weight gain. Network pharmacology analysis suggested that the alkaloids might cause abdominal bloating by affecting the proliferation of smooth muscle cells. The benchmark dose lower confidence limits (based on body weight inhibition) of TAZF were 1.27\u2009g\/kg (male) and 1.91\u2009g\/kg (female).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TAZF has no notable liver or kidney toxicity but carries risks of gastrointestinal and immune toxicity at high doses. Alkaloids from <jats:italic>Coptis chinensis<\/jats:italic> are the main plasma components related to the toxic effects of TAZF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-022-03684-0","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:02:39Z","timestamp":1660536159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Toxicity and toxicokinetics of the ethanol extract of Zuojin formula"],"prefix":"10.1186","volume":"22","author":[{"given":"Shuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"issue":"5","key":"3684_CR1","first-page":"626","volume":"35","author":"C Zhu","year":"2019","unstructured":"Zhu C, Shi W, Chen Y, Zhu X. Clinical application and experimental research progress of Zuojin pill. J Pract Tradit Chin Med. 2019;35(5):626\u20139.","journal-title":"J Pract Tradit Chin Med"},{"issue":"5","key":"3684_CR2","first-page":"78","volume":"48","author":"M Guan","year":"2020","unstructured":"Guan M, Xu W, Li H. Advances in modern pharmacology of Zuojin pills. Acta Chin Med Pharmacol. 2020;48(5):78\u201381.","journal-title":"Acta Chin Med Pharmacol"},{"issue":"5","key":"3684_CR3","first-page":"103","volume":"35","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ma C. Research Progress on treatment of gastric ulcer with Zuojin pill. J Pract Tradit Chin Int Med. 2021;35(5):103\u20136.","journal-title":"J Pract Tradit Chin Int Med"},{"key":"3684_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jep.2015.04.017","volume":"173","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang T, Zhu L, Ma C, Wang S. Anti-ulcerogenic effect of Zuojin pill against ethanol-induced acute gastric lesion in animal models. J Ethnopharmacol. 2015;173:459\u201367.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"3684_CR5","first-page":"1162","volume":"29","author":"N Ye","year":"2014","unstructured":"Ye N, Liu X, Li Q. Experimental research progress of Zuojinwan and its active constituents in anti gastric cancer. China J Tradit Chin Med Pharm. 2014;29(4):1162\u20134.","journal-title":"China J Tradit Chin Med Pharm"},{"issue":"3","key":"3684_CR6","first-page":"609","volume":"34","author":"J Zhang","year":"2018","unstructured":"Zhang J, Li Q. Progress of antitumor mechanism of Zuojin pills. J Changchun Univ Chin Med. 2018;34(3):609\u201312.","journal-title":"J Changchun Univ Chin Med"},{"issue":"2","key":"3684_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jep.2013.05.011","volume":"148","author":"QS Wang","year":"2013","unstructured":"Wang QS, Ding SL, Mao HP, Cui YL, Qi XJ. Antidepressant-like effect of ethanol extract from Zuojin pill, containing two herbal drugs of Rhizoma Coptidis and Fructus Evodiae, is explained by modulating the monoaminergic neurotransmitter system in mice. J Ethnopharmacol. 2013;148(2):603\u20139.","journal-title":"J Ethnopharmacol"},{"key":"3684_CR8","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.jep.2021.114103","volume":"275","author":"Y Wei","year":"2021","unstructured":"Wei Y, Wang R, Ren S, Liu X, Jing M, Li R, et al. Zuojin pill ameliorates inflammation in indomethacin-induced gastric injury via inhibition of MAPK pathway. J Ethnopharmacol. 2021;275:114103.","journal-title":"J Ethnopharmacol"},{"key":"3684_CR9","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.2147\/DDDT.S323360","volume":"15","author":"K Wang","year":"2021","unstructured":"Wang K, Miao X, Kong F, Huang S, Mo J, Jin C, et al. Integrating network pharmacology and experimental verification to explore the mechanism of effect of Zuojin pills in pancreatic Cancer treatment. Drug Design Dev Ther. 2021;15:3749\u201364.","journal-title":"Drug Design Dev Ther."},{"issue":"4","key":"3684_CR10","first-page":"881","volume":"29","author":"S Zhang","year":"2018","unstructured":"Zhang S, Liu S, Zhong Z, Chen B, Wei H. The relationship of\u201cdose -time-toxicity\u201dof different processed products of Evodia rutaecarpa ( Juss.) Benth on hepatotoxicity in mice. Lishizhen Med Mater Med Res. 2018;29(4):881\u20134.","journal-title":"Lishizhen Med Mater Med Res"},{"issue":"3","key":"3684_CR11","first-page":"55","volume":"38","author":"R Sun","year":"2012","unstructured":"Sun R, Huang W, Lv L. Study on the \u201cdose-time-toxicity\u201d relationship of Evodia rutaecarpa volatile oil single administration on liver toxicity in mice. Pharmacol Clin Chin Mater Med. 2012;38(3):55\u20138.","journal-title":"Pharmacol Clin Chin Mater Med"},{"issue":"5","key":"3684_CR12","first-page":"96","volume":"28","author":"W Huang","year":"2012","unstructured":"Huang W, Sun R, Lv L, Bao Z, Wang H. Study on the \u201cdose-time-toxicity\u201d relationship of single administration of Evodia rutaecarpa water extract on liver toxicity in mice. Pharmacol Clin Chin Mater Med. 2012;28(5):96\u20139.","journal-title":"Pharmacol Clin Chin Mater Med."},{"issue":"15","key":"3684_CR13","first-page":"2223","volume":"37","author":"W Huang","year":"2012","unstructured":"Huang W, Li X, Sun R. Study on the \u201cdose-time-toxicity\u201d relationship of multiple administration of aqueous extract of Evodia rutaecarpa on liver toxicity in mice. China J Chin Mater Med. 2012;37(15):2223\u20137.","journal-title":"China J Chin Mater Med"},{"issue":"10","key":"3684_CR14","first-page":"2689","volume":"51","author":"L Liu","year":"2020","unstructured":"Liu L, Zhang X, Xu J, Zhang J, Zhang T, Chen C, et al. Chemical components and pharmacological action for Euodiae Fructus and predictive analysis on its Q-marker. Chin Tradit Herbal Drugs. 2020;51(10):2689\u2013701.","journal-title":"Chin Tradit Herbal Drugs"},{"key":"3684_CR15","unstructured":"ICH M3 (R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.\u00a02010. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines."},{"key":"3684_CR16","unstructured":"CFDA [Z]GPT3-1 Long-term Toxicity Research of Traditional Chinese Medicine and Natural Drugs.\u00a02005. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=ff6f1f9d4b75625297e6dc68ecba4f02."},{"key":"3684_CR17","unstructured":"ICH M3(R2) Guidance for Industry M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceutical.\u00a0\u00a01997. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines."},{"issue":"1","key":"3684_CR18","doi-asserted-by":"publisher","first-page":"017002","DOI":"10.1289\/EHP1289","volume":"126","author":"K Shao","year":"2018","unstructured":"Shao K, Shapiro AJ. A web-based system for Bayesian benchmark dose estimation. Environ Health Perspect. 2018;126(1):017002.","journal-title":"Environ Health Perspect"},{"key":"3684_CR19","first-page":"58","volume":"20","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Zhou J, Huo M. A pharmacokinetic data analysis program based on Excel -- Writing and verification of pkslover 1.0. J Mathematical Med. 2007;20:58\u201361.","journal-title":"J Mathematical Med"},{"issue":"10","key":"3684_CR20","first-page":"140","volume":"28","author":"Q Qiang","year":"2015","unstructured":"Qiang Q, Sheng L, Zhang B, Wang W. Classification of intestinal obstruction and its diagnostic methods. Western J Tradit Chin Med. 2015;28(10):140\u20132.","journal-title":"Western J Tradit Chin Med"},{"issue":"6","key":"3684_CR21","first-page":"50","volume":"21","author":"J Fan","year":"2010","unstructured":"Fan J, Qin J, Liu C, Tang X, Tian H, Liu Y, et al. Establishment of normal reference range of blood hematological and biochemical indicators of SPF wistar rats. J Public Health Prev Med. 2010;21(6):50\u20132.","journal-title":"J Public Health Prev Med"},{"issue":"3","key":"3684_CR22","doi-asserted-by":"publisher","first-page":"e0194979","DOI":"10.1371\/journal.pone.0194979","volume":"13","author":"B Buchanan","year":"2018","unstructured":"Buchanan B, Meng Q, Poulin MM, Zuccolo J, Azike CG, Gabriele J, et al. Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. PLoS One. 2018;13(3):e0194979.","journal-title":"PLoS One"},{"issue":"7","key":"3684_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/bmc.3652","volume":"30","author":"G Li","year":"2016","unstructured":"Li G, Yang F, Liu M, Su X, Zhao M, Zhao L. Development and application of a UPLC-MS\/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administration in rats. Biomed Chromatogr. 2016;30(7):1075\u201382.","journal-title":"Biomed Chromatogr"},{"key":"3684_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jpba.2016.09.022","volume":"132","author":"Y Hu","year":"2017","unstructured":"Hu Y, Fan S, Liao X, Chen C, Su L, Li X. Pharmacokinetics, excretion of 8-cetylberberine and its main metabolites in rat urine. J Pharm Biomed Anal. 2017;132:195\u2013206.","journal-title":"J Pharm Biomed Anal"},{"key":"3684_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jchromb.2015.09.033","volume":"1006","author":"M Liu","year":"2015","unstructured":"Liu M, Su X, Li G, Zhao G, Zhao L. Validated UPLC-MS\/MS method for simultaneous determination of simvastatin, simvastatin hydroxy acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of simvastatin combined with berberine after oral administration in rats. J Chromatogr B. 2015;1006:8\u201315.","journal-title":"J Chromatogr B"},{"issue":"5","key":"3684_CR26","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jpba.2005.09.023","volume":"40","author":"T Lu","year":"2006","unstructured":"Lu T, Liang Y, Song J, Xie L, Wang GJ, Liu XD. Simultaneous determination of berberine and palmatine in rat plasma by HPLC-ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the pharmacokinetic application of the method. J Pharm Biomed Anal. 2006;40(5):1218\u201324.","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"3684_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3109\/00498254.2011.597456","volume":"41","author":"Y Guo","year":"2011","unstructured":"Guo Y, Li F, Ma X, Cheng X, Zhou H, Klaassen CD. CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica. 2011;41(11):996\u20131005.","journal-title":"Xenobiotica."},{"issue":"3","key":"3684_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/bdd.1835","volume":"34","author":"H Zhou","year":"2013","unstructured":"Zhou H, Shi R, Ma B, Ma Y, Wang C, Wu D, et al. CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes. Biopharm Drug Dispos. 2013;34(3):176\u201385.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"3684_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/00498254.2020.1867928","volume":"51","author":"W Xiao","year":"2021","unstructured":"Xiao W, Deng Z, Lai C, Lu H, Huang M, Wen Y, et al. Inhibitory effect of ketoconazole, quinidine and 1-aminobenzotriazole on pharmacokinetics of l-tetrahydropalmatine and its metabolite in rats. Xenobiotica. 2021;51(4):447\u201354.","journal-title":"Xenobiotica."},{"key":"3684_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jpba.2014.09.015","volume":"102","author":"J Vrba","year":"2015","unstructured":"Vrba J, Papouskova B, Pyszkova M, Zatloukalova M, Lemr K, Ulrichova J, et al. Metabolism of palmatine by human hepatocytes and recombinant cytochromes P450. J Pharm Biomed Anal. 2015;102:193\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"3684_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ptr.3554","volume":"26","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Hellum BH, Liang A, Nilsen OG. The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine. Phytother Res. 2012;26(2):277\u201383.","journal-title":"Phytother Res"},{"issue":"2","key":"3684_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/00498254.2014.953624","volume":"45","author":"SY Lee","year":"2015","unstructured":"Lee SY, Jang H, Lee JY, Ma JY, Oh SJ, Kim SK. Inhibitory effects of Hwang-Ryun-Hae-Dok-Tang on cytochrome P450 in human liver microsomes. Xenobiotica. 2015;45(2):131\u20138.","journal-title":"Xenobiotica."},{"issue":"9","key":"3684_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.biopha.2007.02.009","volume":"62","author":"X Zhao","year":"2008","unstructured":"Zhao X, Zhang JJ, Wang X, Bu XY, Lou YQ, Zhang GL. Effect of berberine on hepatocyte proliferation, inducible nitric oxide synthase expression, cytochrome P450 2E1 and 1A2 activities in diethylnitrosamine- and phenobarbital-treated rats. Biomed Pharmacother. 2008;62(9):567\u201372.","journal-title":"Biomed Pharmacother"},{"key":"3684_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/DDDT.S151660","volume":"12","author":"N Chen","year":"2018","unstructured":"Chen N, Yang XY, Guo CE, Bi XN, Chen JH, Chen HY, et al. The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation. Drug Design Dev Ther. 2018;12:57\u201365.","journal-title":"Drug Design Dev Ther"},{"issue":"2","key":"3684_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jchromb.2007.12.028","volume":"863","author":"Y Deng","year":"2008","unstructured":"Deng Y, Liao Q, Li S, Bi K, Pan B, Xie Z. Simultaneous determination of berberine, palmatine and jatrorrhizine by liquid chromatography-tandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of coptis-evodia herb couple. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;863(2):195\u2013205.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3684_CR36","first-page":"31","volume":"4","author":"Q Qu","year":"2002","unstructured":"Qu Q, Zhang M. Pharmacokinetics of berberine. Chin Acad Med Magazine Organ. 2002;4:31\u20135.","journal-title":"Chin Acad Med Magazine Organ"},{"key":"3684_CR37","first-page":"3216","volume":"9","author":"Z Xu","year":"2009","unstructured":"Xu Z, Tang Z, Lin Y. Effect ofberberine on the function ofmyosin and on the contractility of intestinal and gastric smooth muscle. Prog Modern Biomed. 2009;9:3216\u201361.","journal-title":"Prog Modern Biomed"},{"key":"3684_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.biopha.2018.05.067","volume":"104","author":"E Mirhadi","year":"2018","unstructured":"Mirhadi E, Rezaee M, Malaekeh-Nikouei B. Nano strategies for berberine delivery, a natural alkaloid of Berberis. Biomed Pharmacother. 2018;104:465\u201373.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3684_CR39","first-page":"190","volume":"40","author":"X Hua","year":"2017","unstructured":"Hua X, Rui J, Ren B. Effects of traditional Chinese medicine Zuojin pill on gastrointestinal system. Drug Eval Res. 2017;40(2):190\u20135.","journal-title":"Drug Eval Res"},{"key":"3684_CR40","doi-asserted-by":"publisher","first-page":"596686","DOI":"10.3389\/fphar.2021.596686","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu Y, Huang J, Zhang Y, Huang Z, Yan W, Zhou T, et al. Therapeutic effects of Berberine hydrochloride on stress-induced diarrhea-predominant irritable bowel syndrome rats by inhibiting neurotransmission in colonic smooth muscle. Front Pharmacol. 2021;12:596686.","journal-title":"Front Pharmacol"},{"issue":"1\u20133","key":"3684_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.regpep.2008.12.008","volume":"155","author":"ZF Cheng","year":"2009","unstructured":"Cheng ZF, Zhang YQ, Liu FC. Berberine against gastrointestinal peptides elevation and mucous secretion in hyperthyroid diarrheic rats. Regul Pept. 2009;155(1\u20133):145\u20139.","journal-title":"Regul Pept"},{"issue":"23","key":"3684_CR42","doi-asserted-by":"publisher","first-page":"13573","DOI":"10.1111\/jcmm.16049","volume":"24","author":"SM Ehteshamfar","year":"2020","unstructured":"Ehteshamfar SM, Akhbari M, Afshari JT, Seyedi M, Nikfar B, Shapouri-Moghaddam A, et al. Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J Cell Mol Med. 2020;24(23):13573\u201388.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"3684_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/aps.2016.125","volume":"38","author":"K Zou","year":"2017","unstructured":"Zou K, Li Z, Zhang Y, Zhang HY, Li B, Zhu WL, et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin. 2017;38(2):157\u201367.","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"3684_CR44","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/ijms22073522","volume":"22","author":"AA Vita","year":"2021","unstructured":"Vita AA, Aljobaily H, Lyons DO, Pullen NA. Berberine delays onset of collagen-induced arthritis through T cell suppression. Int J Mol Sci. 2021;22(7):3522.","journal-title":"Int J Mol Sci"},{"key":"3684_CR45","doi-asserted-by":"publisher","first-page":"113211","DOI":"10.1016\/j.jep.2020.113211","volume":"262","author":"BG Zhou","year":"2020","unstructured":"Zhou BG, Liu FC, Zhao HM, Zhang XY, Wang HY, Liu DY. Regulatory effect of Zuojin pill on correlation with gut microbiota and Treg cells in DSS-induced colitis. J Ethnopharmacol. 2020;262:113211.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"3684_CR46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/1547691X.2015.1058306","volume":"13","author":"M Mahmoudi","year":"2016","unstructured":"Mahmoudi M, Zamani Taghizadeh Rabe S, Balali-Mood M, Karimi G, Memar B, Rahnama M, et al. Immunotoxicity induced in mice by subacute exposure to berberine. J Immunotoxicol. 2016;13(2):255\u201362.","journal-title":"J Immunotoxicol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03684-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03684-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03684-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T05:04:13Z","timestamp":1660539853000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03684-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3684"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03684-0","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experimental procedures were approved by Peking University Medical Ethical Review Committee (No. LA2018313). Animals were cared for in accordance with the principles of the Guide to the Care and Use of Experimental Animals (Committee on Care and Use of Laboratory Animals, 1985) and were carried out in compliance with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}